CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the first patient of a new Phase 1b/2 clinical trial for its metastatic triple-negative breast cancer treatment leronlimab reported encouraging initial results. Pourhassan says the Vancouver, Washington-based biotechnology company will now look to next file a breakthrough designation with the FDA.
0 Comments